Decreased bone density in men on methadone maintenance therapy

Addiction

Volumn 106, Issue 2, 2011, Pages 349-354

  Grey, Andrew ^a   Rix Trott, Karla ^b   Horne, Anne ^a   Gamble, Greg ^a   Bolland, Mark ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Bone density; Bone formation; Bone resorption; Methadone; Opioids; Osteoporosis

Indexed keywords

BIOLOGICAL MARKER; METHADONE; OSTEOCALCIN; TESTOSTERONE;

ADULT; ARTICLE; BLOOD; BONE; BONE DENSITY; BONE REMODELING; CONTROL GROUP; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; RISK FACTOR; SEX DIFFERENCE;

ABSORPTIOMETRY, PHOTON; ADULT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CONTROL GROUPS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OSTEOCALCIN; OSTEOPOROSIS; RISK FACTORS; SEX FACTORS; TESTOSTERONE;

EID: 78650843730     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03159.x     Document Type: Article

References (30)

1. Perez-Castrillon J. L., Olmos J. M., Gomez J. J., Barrallo A., Riancho J. A., Perera L. et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 2000; 72: 187-94.
2. Mendelson J. H., Mendelson J. E., Patch V. D. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 1975; 192: 211-17.
3. Bliesener N., Albrecht S., Schwager A., Weckbecker K., Lichtermann D., Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005; 90: 203-6.
4. Daniell H. W. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3: 377-84.
5. Compston J. Smoking and the skeleton. J Clin Endocrinol Metab 2007; 92: 428-9.
6. Gennari C., Martini G., Nuti R. Secondary osteoporosis. Aging Clin Exp Res 1998; 10: 214-24.
7. Reid I. R. Relationships among body mass, its components, and bone. Bone 2002; 31: 547-55.
8. Kim T. W., Alford D. P., Malabanan A., Holick M. F., Samet J. H. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85: 258-62.
9. Arnsten J. H., Freeman R., Howard A. A., Floris-Moore M., Santoro N., Schoenbaum E. E. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42: 1014-20.
10. Ensrud K. E., Blackwell T., Mangione C. M., Bowman P. J., Bauer D. C., Schwartz A. et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163: 949-57.
11. Shorr R., Griffin M., Daugherty J., Ray W. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol 1992; 47: M111-M5.
12. Guo Z., Wills P., Viitanen M., Fastbom J., Winblad B. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community based prospective study. Am J Epidemiol 1998; 148: 887-92.
13. Henry M. J., Pasco J. A., Korn S., Gibson J. E., Kotowicz M. A., Nicholson G. C. Bone mineral density reference ranges for Australian men: Geelong osteoporosis study. Osteoporos Int 2009.
14. Henry M., Pasco J., Pocock N. A., Nicholson G., Kotowicz M. Reference ranges for bone densitometers adopted Australia-wide: Geelong osteoporosis study. Australas Radiol 2004; 48: 473-5.
15. Henry M. J., Pasco J. A., Nicholson G. C., Kotowicz M. A. Prevalence of osteoporosis in Australian women. J Clin Density 2000; 3: 261-8.
16. Bolland M. J., Grey A. B., Horne A. M., Briggs S. E., Thomas M. G., Ellis-Pegler R. B. et al. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 2006; 65: 191-7.
17. Glover S. J., Garnero P., Naylor K., Rogers A., Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008; 42: 623-30.
18. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.
19. Kanis J. A., Oden A., Johansson H., Borgstrom F., Strom O., McCloskey E. FRAX and its applications to clinical practice. Bone 2009; 44: 734-43.
20. Nguyen N. D., Frost S. A., Center J. R., Eisman J. A., Nguyen T. V. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19: 1431-44.
21. Reid I. R., Wattie D. J., Evans M. C., Stapleton J. P. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-7.
22. Cicero T. J., Bell R. D., Wiest W. G., Allison J. H., Polakoski K., Robins E. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975; 292: 882-7.
23. Ragni G., De Lauretis L., Bestetti O., Sghedoni D., Gambaro V. Gonadal function in male heroin and methadone addicts. Int J Androl 1988; 11: 93-100.
24. Smith M. R., McGovern F. J., Zietman A. L., Fallon M. A., Hayden D. L., Schoenfeld D. A. et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-55.
25. Daniell H. W. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008; 9: 28-36.
26. Schmittner J., Schroeder J. R., Epstein D. H., Preston K. L. Menstrual cycle length during methadone maintenance. Addiction 2005; 100: 829-36.
27. Cundy T., Evans M., Roberts H., Wattie D., Ames R., Reid I. R. Bone density in women receiving depot medroxyprogesterone acetate for contraception [Erratum appears in BMJ 1991 July 27;303(6796):220]. BMJ 1991; 303: 13-6.
28. Biller B. M., Baum H. B., Rosenthal D. I., Saxe V. C., Charpie P. M., Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75: 692-7.
29. Wilczek H., Stepan J. Bone metabolism in individuals dependent on heroin and after methadone administration. Cas Lek Cesk 2003; 142: 606-8.
30. Pedrazzoni M., Vescovi P. P., Maninetti L., Michelini M., Zaniboni G., Pioli G. et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) 1993; 129: 42-5.